Register for free to
view the full innovation profile.
This instrument has been thoroughly validated and designed to be used as a drug labeling tool (via FDA criteria). It can measure overall burden of disease and the level of disease
About
Summary The Myotonic Dystrophy Health Index Short Form (MDHI-SF) is a brief survey designed to efficiently measure the overall level of disease burden in a patient with myotonic dystrophy type-1. It covers the 17 areas of greatest importance to the adult myotonic dystrophy population. This instrument was developed and validated through the outcome measures laboratory at the University of Rochester and is based on original questions developed for adult myotonic dystrophy patients (also see UR Tech Id: 6-2189 “The Myotonic Dystrophy Health Index (MDHI)” for a more complete description). This disease-specific patient-reported outcome measure is designed to reliably and responsively measure therapeutic benefits in myotonic dystrophy clinical trials. It may also be used to measure overall patient health in a clinical setting.